UNSPSC 51385806: Tenoxicam

This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z1R9N0A399. European Medicines Agency schedules Tenoxicam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10900MIG. Tenoxicam generally arises in the molecular formula C13H11N3O4S2.

UNSPSC 51385806 Tenoxicam is a Commodity code that in recent state and local practice reflects pharmaceutical procurement across a broad spectrum of drug categories and delivery models rather than tenoxicam specifically. Recent solicitations under this code show state and local governments purchasing naloxone and drug deactivation systems for public health response, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing channels, and exploring direct-to-manufacturer prescription programs to bypass traditional pharmacy benefit manager intermediaries. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across multiple jurisdictions. Work scope spans acute-response pharmaceuticals (naloxone kits), chronic-disease and wellness OTC inventory, and systemic pharmacy benefit program redesign aimed at cost control and supply-chain transparency.

Recent activity concentrates in Florida and the Upper Midwest, with particular strength in Texas and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP for generic multi-source pharmaceuticals and OTC products on January 20, 2026, with responses due March 26, 2026, requiring NDC-level product data, cGMP and DSCSA certification, and relationships with AmerisourceBergen, Cardinal Health, or Morris & Dickson wholesalers. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription contracting outside traditional PBM and GPO channels. Cooperative purchasing vehicles dominate the landscape; single-jurisdiction buys tend to be smaller, acute-response procurements, while statewide and multistate initiatives pursue larger, multi-award contracts with performance penalties and administrative fee structures.